Laboratory biomarkers associated with COVID-19 severity and management

por Keddie, S., Ziff, O., Chou, M.K.L., Taylor, R.L., Heslegrave, A., Garr, E., Lakdawala, N., Church, A., Ludwig, D., Manson, J., Scully, M., Nastouli, E., Chapman, M.D., Hart, M., Lunn, M.P.
Publicado 2020

A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology

por Paterson, R W, Heywood, W E, Heslegrave, A J, Magdalinou, N K, Andreasson, U, Sirka, E, Bliss, E, Slattery, C F, Toombs, J, Svensson, J, Johansson, P, Fox, N C, Zetterberg, H, Mills, K, Schott, J M
Publicado 2016

Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease

por Alawode, D. O. T., Heslegrave, A. J., Ashton, N. J., Karikari, T. K., Simrén, J., Montoliu‐Gaya, L., Pannee, J., O´Connor, A., Weston, P. S. J., Lantero‐Rodriguez, J., Keshavan, A., Snellman, A., Gobom, J., Paterson, R. W., Schott, J. M., Blennow, K., Fox, N. C., Zetterberg, H.
Publicado 2021